## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.60)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Arrowhead Pharmaceuticals (ARWR) Is Down 6.1% After First CNS RNAi Alzheimer’s Trial Dosing – Has The Bull Case Changed?**
- Source: Simply Wall Street | 20251219T120958 | Neutral | Relevance: 100%
- Arrowhead Pharmaceuticals has begun dosing subjects in a Phase 1/2a trial for ARO-MAPT, an RNAi therapy targeting tauopathies like Alzheimer's disease, marking its entry into CNS applications. This new trial, utilizing a subcutaneous injection delivery system to cross the blood-brain barrier, expands Arrowhead's pipeline beyond liver and cardiometabolic indications. While adding a new long-term program, the company's investment narrative still focuses on its TRiM RNAi platform's potential across tissues and managing rising costs amid an unprofitable profile.

**2. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler**
- Source: MarketBeat | 20251217T140857 | Bullish | Relevance: 100%
- Piper Sandler has increased its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $100 from $70, maintaining an "overweight" rating and suggesting a significant upside. This move comes amidst mixed analyst ratings but follows several other price target increases. Insider selling activity, including a large sale by CEO Christopher Anzalone, has also been noted.

**3. Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $100 | ARWR Stock News**
- Source: GuruFocus | 20251217T130857 | Bullish | Relevance: 100%
- Piper Sandler has increased its price target for Arrowhead Pharma (ARWR) to $100 from $70, while maintaining an "Overweight" rating. This 42.86% increase reflects a positive outlook, supported by other analysts who have also raised their price targets for the biotechnology company focused on genetic disease treatments. Despite this, the average analyst target suggests a slight downside from its current price, and GuruFocus estimates indicate a potential downside in fair value.

**4. Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch**
- Source: Investing.com India | 20251217T130857 | Bullish | Relevance: 100%
- Piper Sandler has increased its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $100 from $70, maintaining an Overweight rating and naming it a "Top Pick for 2026" due to the Redemplo launch and upcoming SHTG data. The firm projects significant sales for Redemplo following its launch for Familial Chylomicronemia Syndrome (FCS) and anticipates positive Phase III data for severe hypertriglyceridemia (SHTG) in Q3 2026, which could lead to "blockbuster label expansion." This positive outlook is further supported by Arrowhead's strong cash position and additional pipeline developments, reflecting a confident analyst sentiment despite recent varying price targets from other firms.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.6% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.7M in recent transactions.
3. Elevated short interest (11.3%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 9 raises (avg +37%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -27% YoY, concerning. Analyst sentiment positive (9 raises, avg +37%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 4.7% to 0.1% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.14% (CS: 56) | Neutral |
| RSI_14 | 67.7 | Neutral |
| MACD Histogram | -0.41 | Bearish |
| vs SMA20 | 1.111x | Above |
| vs SMA50 | 1.419x | Above |
| vs SMA200 | 2.619x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $68.16
- **Stop Loss:** $59.60 (12.6% risk)
- **Target:** $76.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 140
- **Position Value:** $9,542.40
- **Portfolio %:** 9.54%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*